Chrong-Reen Wang,Hung-Wen Tsai,Wen-Chien Chou et al.
Chrong-Reen Wang et al.
Establishing valid cutoff scores for the Chinese version of the Montgomery-Åsberg Depression Rating Scale in Taiwanese patients with depression [0.03%]
台湾抑郁症患者用蒙特利尔-阿斯伯格抑郁评定量表建立中国版本的有效临界分数标准
Ling Chen,Yuqing Cui,Chun-Hsin Chen et al.
Ling Chen et al.
Background/purpose: The Montgomery-Åsberg Depression Rating Scale (MADRS) is widely used for assessing depression severity, but its validity and optimal cutoff scores have not been established for Taiwanese populations. ...
Comment on "Hope and its relationship with treatment/physical related factors in lung cancer patients receiving immunotherapy" [0.03%]
关于“希望及其与接受免疫治疗的肺癌患者治疗/身体相关因素的关系”的评论
Qianqian Yin,Zhongqi Wang
Qianqian Yin
Micro-elimination of hepatitis C in patients with chronic kidney disease and diabetes in Taiwan [0.03%]
台湾慢性肾病和糖尿病患者的微小肝炎C消除行动
Kuo-Chin Chang,Yen-Po Yeh,Shiou-Shiang Chen et al.
Kuo-Chin Chang et al.
National governments across the globe are devising strategies to achieve the World Health Organization (WHO) goal of hepatitis C virus (HCV) elimination by 2030. The Taiwan government has also set an ambitious target of reaching 80 % treatm...
Etiological identification of Rickettsia typhi and Coxiella burnetii by metagenomic next-generation sequencing among adults with acute febrile illness in southern Taiwan [0.03%]
通过宏基因组高通量测序技术在台湾南部成人急性发热患者中对恙虫病东方体和贝纳氏立克次体的病因鉴定
Tian-Yu You,Ying-Wen Chen,Szu-Ying Chen et al.
Tian-Yu You et al.
Comment on Home-based rehabilitation versus hospital-based rehabilitation for stroke patients in post-acute care stage: Comparison on the quality of life [0.03%]
关于急性期后卒中患者进行居家康复和医院康复的对照研究:生活质量比较
Zhang Miaomiao,Bai Yanlai
Zhang Miaomiao
Long-term survival of patients who received atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma [0.03%]
阿特珠单抗联合贝伐珠单抗治疗晚期肝细胞癌患者的长期生存分析
Ching-Tso Chen,Yin-Hsun Feng,Chia-Jui Yen et al.
Ching-Tso Chen et al.
Background: Immunotherapy combinations, such as atezolizumab plus bevacizumab (Atezo-Bev) or durvalumab plus tremelimumab, have been established as standard treatments for patients with advanced hepatocellular carcinoma (...
Highlights [0.03%]
亮点
Jia-Horng Kao
Jia-Horng Kao
Prevalence of seropositive occult hepatitis B virus infection among patients received chemotherapy in Taiwan: A retrospective study [0.03%]
台湾化疗患者中隐匿性乙肝病毒感染的血清学阳性流行病学研究:回顾性研究
Pei-Yuan Su,Chih-Wen Huang,Ya-Huei Zeng et al.
Pei-Yuan Su et al.
Background: Occult hepatitis B virus (HBV) infection (OBI), defined by the presence of HBV DNA in the absence of hepatitis B surface antigen (HBsAg), poses a risk for viral reactivation during cancer therapy. Although HBV...